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ds.2012.1Abstract Progressive familial intrahepatic cholestasis refers to a heterogenous group of autosomal
recessive disorders in which children develop severe intrahepatic cholestasis progressing to biliary
cirrhosis and chronic liver failure, usually during the ﬁrst decade of life. The clinical features include
jaundice, hepatomegaly, splenomegaly, growth retardation and severe pruritus. The laboratory tests
demonstrate elevated bilirubin, bile acids and liver function enzymes. The only curative treatment
of progressive familial intrahepatic cholestasis is liver transplantation.
This article presents the medical and dental history along with a comprehensive dental manage-
ment and prognosis of a 6 years old male patient with progressive familial intrahepatic cholestasis
type I and liver cirrhosis 5 years post living related liver transplant in Riyadh, Saudi Arabia. The
patient demonstrated improved oral hygiene performance during the course of treatment, and con-
tinued to demonstrate a low caries rate up to 7 months following treatment. Based upon the appar-
ent success of the preventive programme, the patient was judged to have a very good prognosis.
 2012 King Saud University. Production and hosting by Elsevier B.V.Open access under CC BY-NC-ND license.1. Review of the literature
Progressive familial intrahepatic cholestasis (PFIC) is a class of
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1.008idly progress and cause liver cirrhosis within the ﬁrst decade of
life, or may progress relatively slowly with minimal scarring
well into adolescence. Few patients have survived into the third
decade of life without treatment [5,17]. The onset of the disease
is usually before age two, the average age of onset is 3 months,
although some patients do not develop jaundice until later,
even as late as adolescence.
Originally, Clayton et al. [6] described the PFIC disorder
in large Amish kindred, descendants of Jacob Byler and
henceforth the term ‘‘Byler’s disease’’ has been used to de-
scribe the condition. Subsequently, numerous phenotypically
similar non-Amish patients were reported, and have thus
been superseded by the term progressive familial intrahepatic
cholestasis.ier B.V. Open access under CC BY-NC-ND license.
38 H. AbuBotain, R. KhounganianAt present, speciﬁc gene defects have been identiﬁed for
three subtypes of PFIC. The inheritance pattern of all three
forms of PFIC deﬁned to date is autosomal recessive. Despite
their genetic distinctiveness, PFIC type I (formerly known as
Byler’s disease) and PFIC type II have few clinical differences,
and both are caused by the absence of a gene product required
for canalicular export and bile formation. Rather than defec-
tive bile acid export, patients with PFIC type III have deﬁcient
hepatocellular phospholipid export. The lack of phospholipids
produces unstable micelles that have a toxic effect on the bile
ducts, leading to bile duct plugs and biliary obstruction
[4,18,15].
Of the three entities, PFIC type III is the most severe type
which usually presents in early childhood with cholestasis,
jaundice, and failure to thrive. Intense pruritus is characteris-
tic of adolescent patients; it has been linked with suicide.
Patients may have fat malabsorption, leading to fat soluble
vitamin deﬁciency, and complications, including osteopenia
[33].
Clinically, progressive familial intrahepatic cholestasis in-
cludes jaundice and severe itching caused by the build-up of
bile salt in the body, poor weight gain and poor growth. Other
symptoms may include abnormal enlargement of the liver and
spleen, poor feeding, nausea and vomiting [36].
Biochemical markers include a normal gamma-glutamyl
peptidase (GGT) for PFIC type I and PFIC type II, with a
markedly elevated GGT for PFIC type III. Serum bile acid lev-
els are grossly elevated. Serum cholesterol levels are typically
not elevated [23].
Pathogenesis is based on a defect in hepatic metabolism,
perhaps a defect in transport, formation or excretion of pri-
mary bile acids where children are unable to drain bile from
the liver even though the large bile ducts are open [35].
Hepatocellular carcinoma may develop in PFIC type II at a
very early age [11,22]; even toddlers have been affected. The
disease is typically progressive, leading to fulminant liver fail-
ure and death in childhood in the absence of liver transplanta-
tion [34].
The recent improvement in survival rates following liver
transplantation has led to a remarkable increase in the num-
bers of paediatric liver transplants being undertaken world-
wide [20]. Because most of these children are medically
compromised at the time of transplantation, dental decay, den-
tal infections or prematurely missing teeth often associated
with inadequate nutrition may further jeopardize their general
health while they receive immunosuppressive medications
[32,13].
This article presents the medical and dental history along
with a comprehensive dental management and prognosis over
a period of 7 months follow-up of a 6 years old male patient
with progressive familial intrahepatic cholestasis type I and
liver cirrhosis 5 years post living related liver transplant in
Riyadh, Saudi Arabia.
2. Case report
A 6 year old Saudi male patient with post living related liver
transplant from his uncle secondary to progressive familial
intrahepatic cholestasis type I was referred to the medically
compromised paediatric dental clinic at the Riyadh Military
Hospital complaining of pain related to his teeth due to multi-
ple caries and poor oral hygiene.Based upon the clinical examination, the patient was diag-
nosed as having multiple carious teeth, remaining roots and
abscess related to deciduous maxillary right central and lateral
incisors and excessive reﬁned sugar intake between meals.
Moreover; he revealed poor oral hygiene and low dental home
proﬁle.
He was referred back to his physician for medical consulta-
tion for the presence of any contraindications for dental treat-
ment. His physician indicated that the patient needs oral
antibiotic coverage Amoxil 30 mg/kg one dose before each
dental session. Appropriate laboratory investigations (CBC,
PT, PTT, INR, bleeding time, and liver function tests) were
reviewed prior to dental treatment.
A comprehensive dental treatment was planned for all the
teeth to receive appropriate care in order to maintain good
oral hygiene and proper occlusion.
2.1. Medical history
The parents were young aged and ﬁrst degree relatives with a
history of consanguinity. The patient has two older siblings;
the brothers underwent liver transplantation secondary to
PFIC type I with no other hereditary familial disease.
At the age of 2 months, signs of jaundice were noted in his
eyes and face and gradually progressed to involve the upper
chest and with deep stained yellow under urine. No changes
to stool corrector were noted. The patient was referred to King
Faisal Specialist Hospital and Research Centre where he
underwent investigational procedures and was advised to fol-
low up––A liver metabolic disease was suspected. No medica-
tions were given till the age of 6 months. Patient was
requested to consult the Riyadh Military Hospital liver trans-
plant clinic because he developed intense progressive itching as
well as failure to thrive with the persistence of the aforemen-
tioned symptoms.
The patient was diagnosed with PFIC type I on the basis of
the history of laboratory reports of liver function test, ultra-
sound and family history. He was prescribed ursodeoxycholic
acid and alpha calcidol with a regular follow up protocol.
At the age of 1 year, the patient was admitted to the hospi-
tal for liver transplant from a living related uncle as a liver
donor. The patient was moved to the paediatric liver trans-
plant ward, with a slight elevation of the liver enzymes. He
was under antibiotics as postoperative prophylaxis to avoid
susceptibility to infection and tacrolimus as an immunosup-
pressant therapy to minimize the risk of rejection.
He underwent a graft biopsy 14 days following transplant
surgery, which revealed mild rejection. He was put on anti-
rejection therapy methyl prednisolone for 5 days after which
he started to show normalizing liver enzymes. Later that year
the patient was admitted with mild grade fever, skin rashes
over the extremities and vesicles around the lip. He was diag-
nosed with Varicella Zoster infection. During hospitalization,
he received Acyclovir for 7 days (10 mg/kg IBW intravenous
every 8 h) and then shifted to oral Valaciclovir at a dose of
500 mg TDS. At the age of 3 years and 5 months, the patient
was hospitalized due to acute mild rejection status post liver
transplant with high liver enzymes. He was put on intravenous
gancyclovir for 1 week and discharged on oral vagancyclovir,
his liver enzymes were good.
To this date he is undergoing regular check-up and follow-
ups with his physician. Moreover, he is on a number of
Dental management of a patient with progressive familial intrahepatic cholestasis 39medications; Bactrim 200/40 mg (3 times/week) as an effective
antibiotic that covers a wide range of gram positive and neg-
ative pathogenic organisms to avoid infections; Prograf
(tacrolimus) 0.5 mg (2 capsules/day) as an immunosuppressant
to minimize the risk of rejection; Ursofalk 250 mg/5 ml (once/
day) as it alters the composition of bile and increases its
concentration, decreases the amounts of toxic bile acids and
increases bile ﬂow.
2.2. Dental history
The patient’s ﬁrst visit to the dental clinic was at the age of
6 years. He had not received any previous dental examination,
preventive care or restorations. No history of trauma of pri-
mary dentition or abnormal oral habits such as tongue thrust-
ing and mouth breathing were reported. He was cooperative in
the ﬁrst dental visit and he had a friendly personality. He was
reasonably relaxed with minimal apprehension indicating that
he can be treated by a straight forward, behaviour-shaping
approach.
The patient’s height (113 cm) and weight (17 kg) were re-
corded and the physical growth percentile chart (NCHS) was
calculated; his height represented 25% of his age, and his
weight 10% of his age.
The head and neck evaluation revealed a symmetrical face
with a convex facial proﬁle (Fig. 1). There was no discernible
facial pathology. The examination of the Temporomandibular
joint revealed no tenderness or joint noise and jaw opening oc-
curred smoothly without any deviation through a full range of
movements. No enlarged lymph nodes were palpated in the
neck or the submandibular area. The cheeks and lips were of
normal colour and no abnormalities were visually detected
or by palpation. He appeared to have good muscle balance
during swallowing. His hair nails, and hands appeared within
normal.
Intraoral soft tissue examination revealed no apparent
abnormalities of the tongue, ﬂoor of the mouth, palate, oro-
pharynx, or buccal mucosa. The labial and lingual frena
appeared within normal. The tonsils were not enlarged or
infected. Generalized plaque induced gingivitis and greenish
discoloration of the teeth and gingiva was noticed.Figure 1 Pre-treatment eAn evaluation of the occlusion revealed a mixed dentition
with the maxillary and mandibular dental arches in well-
formed ‘‘U-shaped’’ arches. In centric occlusion, the primary
molar relationships on the right and left side were in mesial
step relationships. The primary cuspids relationship on the
right side was in class III and the left side was in class I rela-
tionships. There was no cross bite, over jet and open bite were
not applicable due to the presence of badly broken down teeth.
Lower and upper midlines were not coincident; the lower mid-
line was shifted to the left side by 2 mm. There was no mandib-
ular displacement. Dental examination revealed no missing
teeth, presence of multiple carious teeth and remaining roots
with abscess related to deciduous maxillary right central and
lateral incisors. He had plaque accumulation, poor oral
hygiene and low dental home proﬁle with a history of excessive
reﬁned sugar intake between meals (Fig. 2).
Two bitewings, an upper anterior and four posterior peri-
apical radiographs were taken and evaluated. Carious lesions
were revealed on the occlusal and proximal surfaces of decid-
uous maxillary and mandibular right and left ﬁrst and second
molars, as well as the remaining roots of deciduous maxillary
right central and lateral incisors and deciduous maxillary left
lateral incisor with periapical abscesses (Fig. 3).
2.3. Treatment plan
The function of occlusion was re-established by restoring all
carious teeth. Deciduous maxillary right and left canines and
deciduous mandibular right canine were restored with compos-
ite restorations (Z100, shade A2). Deciduous maxillary right
and left ﬁrst and second molars, deciduous mandibular right
and left ﬁrst molars and right second molar were treated with
pulp therapy and stainless steel crowns. Deciduous maxillary
right lateral incisor and the right and left central incisors were
extracted. Deciduous maxillary left lateral incisor was badly
broken down and non-restorable, was also extracted. Decidu-
ous mandibular left second molar was restored with an occlu-
sal amalgam restoration and ﬁssure sealant instead of stainless
steel crown as the cavity was not extensive and included one
surface. Fissure sealant was applied to the permanent maxil-
lary left ﬁrst molar after etching with 32% phosphoric acid,xtraoral photographs.
Figure 2 Pre-treatment intraoral photographs.
Figure 3 Pre-treatment radiographs.
40 H. AbuBotain, R. Khounganiandentin adhesive resin (single bond) to increase the tensile
strength of the bonding. Fissure sealant application of the car-
ies free ﬁrst permanent molars was applied as soon as they
were sufﬁciently erupted (Fig. 4).
Careful examination of the head and neck region was per-
formed as organ transplant patients have an increased risk of
oral malignancy [30,11]. The patient was instructed and
encouraged to maintain good oral hygiene by scrub brushing
technique using ﬂuoridated tooth paste and multitufted soft
Nylon toothbrush (twice per day) and ﬂossing under parental
observation (once at night) in order to achieve a proper dental
home proﬁle and good oral hygiene and to allow the resolution
of the gingival inﬂammation. Diet advice and nutrition assess-
ment were carried out.All dental treatments were performed as planned under low
doses of local anaesthesia. The duration of the treatment was
expanded over seven visits and two recall follow ups.
In the three and seven month recall visits, there were no
apparent changes in the medical history since the last visit.
Intra and extra oral examinations were performed (Figs. 5
and 6). There was no evidence of new clinical carious lesions,
intact restorations and no complaint regarding the previous
dental restorations.
At 3 months recall, the panoramic radiograph revealed the
absence of supernumerary teeth, ectopic eruption, impaction
or any pathological condition (Fig. 7). Number of permanent
teeth was complete and the child had a normal eruption age
compared to his chronological age. The tooth follicles of the
Figure 5 Three months extraoral and intraoral recall photographs.
Figure 4 Post-treatment intraoral photographs.
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Upper and lower permanent canines appeared to be normally
erupting. No Temporomandibular joint abnormalities were
detected at either side (Fig. 7).
Periapical and bitewings were also taken at 7 months. No
apparent recurrent, proximal caries or new carious lesions
were detected (Fig. 8).
Fissures and grooves of permanent maxillary right ﬁrst
molar and mandibular right and left ﬁrst molar were cleaned,
etched with 32% phosphoric acid, dentin adhesive resin (singlebond), and ﬁssure sealant was applied. Furthermore; reinforce-
ment of oral hygiene instructions and nutrition assessment was
performed.
3. Discussion
Progressive familial intrahepatic cholestasis is an autosomal
recessive disorder of intrahepatic cholestasis of metabolic and
genetic origin [27,12]. It begins in infancy and usually progresses
to cirrhosis or may progress relatively slowly with minimal
Figure 6 Seven months extraoral and intraoral recall photographs.
Figure 7 Three months recall panoramic radiograph.
42 H. AbuBotain, R. Khounganianscarring well into adolescence [35]. Few patients have survived
into the third decade of life without treatment [2,7]. At present,
the only curative treatment of PFIC is liver transplant [25,34].
PFIC is an extremely rare condition and affects only infants
and children with males and females equally affected however
the exact frequency is unknown. Fewer than 200 patients with
PFIC type I or PFIC type II are reported in the medical liter-ature in all races. PFIC type III is extremely rare, with fewer
than 20 reported patients in Western Europe, White and North
African populations. Kagalwalla et al. [19] reported similar
cases in Arab children. Case reports in Moroccan [8] and Pal-
estinian [21] children were also documented. Some cultures
where consanguineous marriages are common have greater
tendencies [9].
Figure 8 Seven months recall radiographs.
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life secondary to their unusually severe pruritus and jaundice,
delayed growth and development. Patients with PFIC type I
may experience a relapsing and remitting course of symptoms,
but permanent cholestasis, ﬁbrosis, and liver failure are inevi-
table without treatment [26]. PFIC type I is also associated
with watery diarrhoea. This secretory diarrhoea may persist
after liver transplantation and may reﬂect an important role
for PFIC type I in the intestine, where it is highly expressed.
Other extra hepatic manifestations associated with PFIC type
I include short stature, sensorineural deafness, pancreatitis,
and hepatic steatosis [14].
It was important to discuss the details of the patient’s condi-
tion with his treating physician in order to provide the patient
with a dental treatment plan that was safe and appropriate for
his medical and dental condition in order to reduce the risk of
systemic infection arising from the oral cavity.
The clinical examination revealed multiple carious and
badly broken teeth, remaining roots and abscesses. He had a
poor oral hygiene and low dental home proﬁle with a history
of excessive reﬁned sugar intake between meals.
The patient was presented with oral manifestations such as
greenish staining of the teeth and the gingiva similar to previ-
ous reports [29,1]. The intrinsic green discoloration of the teeth
is usually due to elevated serum levels of conjugated bilirubin
in liver disease patients. Rosenthal et al. [28] stated that the
green discoloration might also affect intra oral soft tissues
including gingiva, tongue, ﬂoor of the mouth and buccal mu-
cosa. Similar ﬁndings were also reported in a 13 year old
Kuwaiti girl with Alagille syndrome who was presented with
severe discoloration of the teeth that was possibly due to the
medication the child was placed on to reduce graft rejection.
Furthermore, gingival inﬂammation and oedema due to poor
oral hygiene was also reported [1].It is noteworthy to mention that enamel hypoplasia due to
the metabolic disturbances, delayed eruption of teeth; enlarged
pulp chambers and root canals secondary to vitamin D deﬁ-
ciency was previously described by Hosey et al. [16] and Shee-
hy et al. [31].
The occurrence of dental caries in this patient seemed to
be somewhat coinciding with other healthy paediatric
patients of his age. The use of sugar containing oral medica-
tions and the ingestion of excessive fermentable carbohydrate
rich snacks between meals might have been a contributing
factor. Nonetheless, rampant caries has been reported in chil-
dren with biliary atresia and those undergoing liver trans-
plantation [3] due to frequent and prolonged bottle feeding
in the youngsters.
In a study of nine children undergoing liver transplanta-
tion, Seow et al. [29] reported that one had dental caries in
all the primary teeth, the majority of which had dental ab-
scesses, and two other patients had dental caries in at least
three teeth. In another study, rampant caries were associated
with poor oral hygiene [24].
In general, dental management of PFIC may be compli-
cated by many factors, like increased susceptibility of patients
to infection, bleeding tendency, altered drug metabolism
including local anaesthetics, poor wound healing, drug interac-
tions with immunosuppressive therapy and the risk of adrenal
insufﬁciency following prolonged treatment with corticoste-
roids [29].
Potential sources of infections that could cause signiﬁcant
complications were eliminated through the extraction of the
badly decayed and abscessed teeth with minimal amounts
(one carpule) of Lidocaine (xylocaine with 2% epinephrine,
1:80,000). Local anaesthetics were cautiously administered
since most amides are metabolized in the liver and it may reach
toxic level with lower doses of local anaesthesia.
44 H. AbuBotain, R. KhounganianInfection is the most frequent complication following liver
transplantation. Antibiotic prophylaxis is mandatory in chil-
dren with chronic liver failure and in all liver recipients prior
to dental treatment.
The patient was advised by his physician to take oral anti-
biotic Amoxil (30 mg/kg) one dose before each dental session
since Augmentin (Amoxicillin Clavulanate) antibiotic is con-
traindicated in liver transplant patients as it contains clavu-
lanic acid which metabolizes in the liver in addition to his
weekly medications. Analgesics or any other type of medica-
tion was not needed during the course of dental treatment.
Bacteremia arising from invasive dental procedures repre-
sents a signiﬁcant potential degree of risk in the immunocom-
promised patients, even though caution must be used in
prescribing medications, some drugs such as antibiotics (eryth-
romycin, metronidazole, tetracycline), analgesics (acetamino-
phen), antiplatelet (aspirin) and sedatives (barbiturates) that
are metabolized in the liver and or/ impair haemostasis should
be completely avoided. Additionally, non-steroidal anti-
inﬂammatory agents should be cautiously used or avoided
due to an increased risk of gastrointestinal bleeding and inter-
ference with ﬂuid balance [10].
Particular attention should be paid to oral opportunistic
infections such as candidiasis, to avoid the risk of life threaten-
ing septicemia. Patients who have undergone organ transplan-
tation can present with a variety of oral lesions that appear to
be related either directly to their medication or arise as a con-
sequence of drug-induced immunosuppression. An increased
propensity to both fungal and viral infections and a high inci-
dence of malignant change, especially lip cancer were observed
by Seymour et al. [30]. Any modiﬁcations in medication re-
gimes should be made in conjunction with the suggestions of
the treating physician.
During oral surgical procedures, special attention was paid
to minimize trauma and bleeding. The bleeding tendency was
primarily due to impaired synthesis of vitamin K; reduced or
defective synthesis of clotting factors, in particular factors II,
VII, IX and X, increased ﬁbrinolysis; and thrombocytopenia
secondary to portal hypertension and hypersplenism.
4. Outcome and prognosis
The patient demonstrated improved oral hygiene performance
during the course of treatment based upon plaque scores and
tooth brushing and ﬂossing evaluations. No new carious le-
sions were detected between the visits. The duration of the
treatment was expanded over seven visits and two recall follow
ups. The child and his parents were reminded of the impor-
tance of oral hygiene measures and compliment on the child’s
improved hygiene and caries free status.
Based upon the apparent success of this preventive pro-
gramme, the patient was judged to have a very good prognosis
and continued to demonstrate a low caries rate up to 7 months
only following treatment. Unfortunately as the patient and his
family were transferred to another region in the Kingdom, the
follow-up visits were henceforth halted.
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